Updated Single Preferred Drug List (PDL) for Medicaid: A new single Preferred Drug List Formulary became effective April 1. Please note that NC Statute 108D-65(6)(b)  requires all PHPS/Medicaid Plans use the same drug formulary established by the Department.

Blue Cross and Blue Shield of North Carolina published an update on April 5, 2022.

Please join NC DHHS Chief Medical Officer for Behavioral Health & Intellectual & Developmental Disabilities (IDD), Dr. Carrie Brown, NC Medicaid Chief Quality Officer, Kelly Crosbie, and Director of the North Carolina Area Health Education Centers (NC AHEC), Hugh Tilson alongside guest speakers from the provider community for the April Back Porch Chat on Thursday, April 21 from 5:30-6:30 p.m.  

The Northwest AHEC Practice Support Team supports social, physical, and economic environments which promote attaining the full potential of health and well-being for all. This blog segment highlights impactful publications which promote improved health outcomes through Social Determinants of Health (SDOH) each month.

North Carolina currently ranks 30th in the country in maternal mortality and 39th in infant mortality. In addition, 12% of women in the state experience postpartum depression.

You’re Invited to Participate in Medicaid Quality Improvement Work with NC AHEC — your gateway to Population Health Improvement and Shared Savings!

All health plans offer the same basic benefits and services. Some health plans  also offer added services. View health plans  to learn about the added services that each health plan offers.

Save the date for a webinar brought to you by our colleagues at Mountain Area Health Education Center

Lifeline is a federal government program that offers a monthly discount on phone, internet or bundled package bills to qualified low-income people, which can give them the tools to access services like telehealth.  People living on Tribal Lands can receive additional benefit. 

On February 11, 2022,  the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.